Objective: To elucidate the mechanisms of thrombocytopenia in alcoholic liver diseases, we investigated activation status of platelets in patients with alcoholic fatty liver (Al-FL), alcoholic liver cirrhosis (Al-LC) or hepatitis-C liver cirrhosis C (C-LC).
Methods: Platelet activation was evaluated by flow cytometry using monoclonal antibodies against P-selectin (CD62P) and the fibrinogen receptor (PAC-1), both specific for platelet activation, and anti-CD61 antibody for the presence of microparticles (PMP) in seven patients with Al-FL, thirteen patients with Al-LC and, as a non-alcoholic liver disease control, nine patients with C-LC. As a normal control, seventeen healthy subjects without liver dysfunction were also evaluated.
Results: Compared with the healthy controls, the platelet count was significantly decreased in patients with alcoholic liver diseases or C-LC. Ten days after discontinuation of alcohol intake, the platelet count was significantly higher in both the Al-FL and Al-LC groups than that measured on admission. There was an inverse correlation between the platelet count and PMP, a marker of platelet activation. The Al-FL, Al-LC and C-LC groups showed significantly higher percentages of platelets positive for CD62P than the healthy controls. The PAC-1 positivity was increased only in the C-LC group. PMP were significantly increased in the Al-FL, Al-LC and C-LC groups compared to that in the healthy group. In the Al-LC group, PMP were significantly decreased 10 days after discontinuation of alcohol intake from that measured on admission.
Conclusion: Patients with alcoholic liver diseases have increased platelet activation, which may contribute to the occurrence of thrombocytopenia. The formation of PMP might be one of the important factors of thrombocytopenia in alcoholic liver diseases.
Download full-text PDF |
Source |
---|
Anticancer Res
January 2025
Department of Surgery, Fukuoka University Chikushi Hospital, Fukuoka, Japan.
Background/aim: Liver metastasis (LM), pre-dominant in pancreatic cancer, is associated with a dismal 5-year survival rate. Reports on the presence of fatty liver and liver fibrosis in LM are conflicting. Although liver biopsy is the standard diagnostic method for fibrosis, alternative, less invasive scoring models have been explored.
View Article and Find Full Text PDFAnticancer Res
January 2025
Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Background/aim: Lipoprotein(a) (Lp(a)) is a complex protein involved in the transport of insoluble lipids in plasma. Its expression is predominantly genetically determined, with 70% to over 90% influenced by the number of Kringle IV type 2 domains. This study investigated the association between preoperative serum Lp(a) level and development of post-pancreatectomy nonalcoholic fatty liver disease (NAFLD) in patients who underwent pancreatectomy.
View Article and Find Full Text PDFJ Hum Nutr Diet
February 2025
Department of Public Health, Aarhus University, Aarhus C, Denmark.
Background: Dietary recommendations have globally shifted towards promoting the consumption of legumes as an environmentally friendly and healthy source of protein. This study investigated the replacement of red and processed meat, poultry or fish for equal amounts of legumes on the risk of non-alcoholic fatty liver disease (NAFLD).
Methods: UK Biobank participants who completed ≥ 2 dietary assessments and had complete covariate information were included in the analyses (N = 124,546).
PLoS One
December 2024
Ningbo Medical Center Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Background: The evolution of NAFLD, MAFLD, and MASLD underscores significant advancements and nomenclatural shifts in the realm of chronic liver disorders. This study primarily aimed to investigate the possible link between serum selenium levels and the occurrence of MASLD.
Methods: Utilizing data from NHANES for the years 2017 through 2020, we performed an in-depth analysis.
Clin Transl Sci
January 2025
Division of Digestive and Liver Diseases, Department of Medicine, Center for Liver Disease and Transplantation, Columbia University Irving Medical Center, New York, New York, USA.
Nonalcoholic fatty liver disease (NAFLD) is the most common global cause of chronic liver disease and remains under-recognized within healthcare systems. Therapeutic interventions are rapidly advancing for its inflammatory phenotype, nonalcoholic steatohepatitis (NASH) at all stages of disease. Diagnosis codes alone fail to recognize and stratify at-risk patients accurately.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!